Eagle Asset Management Inc. Sells 118,636 Shares of Haemonetics Co. (NYSE:HAE)

Eagle Asset Management Inc. trimmed its holdings in shares of Haemonetics Co. (NYSE:HAE - Free Report) by 54.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 100,565 shares of the medical instruments supplier's stock after selling 118,636 shares during the period. Eagle Asset Management Inc. owned about 0.20% of Haemonetics worth $8,791,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. CANADA LIFE ASSURANCE Co grew its position in shares of Haemonetics by 13.2% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 50,728 shares of the medical instruments supplier's stock valued at $4,330,000 after acquiring an additional 5,933 shares during the period. PEAK6 Investments LLC bought a new stake in shares of Haemonetics in the first quarter valued at $452,000. Price T Rowe Associates Inc. MD lifted its position in shares of Haemonetics by 38.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 562,454 shares of the medical instruments supplier's stock valued at $48,006,000 after buying an additional 156,665 shares during the last quarter. Silvercrest Asset Management Group LLC bought a new position in shares of Haemonetics during the 1st quarter worth $38,706,000. Finally, Janus Henderson Group PLC increased its holdings in Haemonetics by 26.8% in the 1st quarter. Janus Henderson Group PLC now owns 29,730 shares of the medical instruments supplier's stock worth $2,536,000 after acquiring an additional 6,287 shares during the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on HAE shares. JMP Securities reiterated a "market outperform" rating and issued a $125.00 target price on shares of Haemonetics in a research note on Tuesday, August 13th. CL King began coverage on Haemonetics in a research report on Friday, September 13th. They issued a "buy" rating and a $116.00 price target for the company. Needham & Company LLC reaffirmed a "buy" rating and set a $112.00 target price on shares of Haemonetics in a report on Friday, November 15th. Raymond James raised shares of Haemonetics from an "outperform" rating to a "strong-buy" rating and set a $120.00 price target for the company in a report on Friday, November 8th. Finally, BTIG Research started coverage on Haemonetics in a research report on Tuesday, September 10th. They issued a "buy" rating and a $112.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $107.88.

Haemonetics Price Performance

Shares of NYSE HAE traded up $2.91 during trading hours on Monday, reaching $88.46. 484,691 shares of the stock traded hands, compared to its average volume of 556,377. The company has a market capitalization of $4.44 billion, a P/E ratio of 36.21, a price-to-earnings-growth ratio of 1.33 and a beta of 0.32. The company's 50-day simple moving average is $78.75 and its two-hundred day simple moving average is $82.32. The company has a quick ratio of 2.09, a current ratio of 3.49 and a debt-to-equity ratio of 1.39. Haemonetics Co. has a 52-week low of $70.25 and a 52-week high of $97.97.

Haemonetics (NYSE:HAE - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $1.12 earnings per share for the quarter, topping analysts' consensus estimates of $1.09 by $0.03. Haemonetics had a net margin of 9.10% and a return on equity of 22.67%. The firm had revenue of $345.50 million during the quarter, compared to analyst estimates of $342.57 million. During the same period in the previous year, the business posted $0.99 EPS. The business's quarterly revenue was up 8.6% on a year-over-year basis. Equities research analysts forecast that Haemonetics Co. will post 4.59 EPS for the current year.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.